Free Rheumatology CME

  • FREE

    Systemic lupus erythematosus: therapeutic updates and optimizing treatment

    Activity Description / Statement of Need:

    Systemic lupus erythematosus (SLE) is an autoimmune disease with heterogeneous etiologies and clinical phenotypes, all with varying degrees of severity. Although the precise mechanism of SLE-related autoimmunity is still uncertain, strong evidence implicates a combination of genetic and environmental factors in the disease pathology. For most of the medical community, the primary challenges of SLE management stem from the disease heterogeneity, which leads to difficulty in diagnosing, treating, and monitoring.

    Evidence suggests that there are a number of gaps in the treatment of lupus stemming from a suboptimal patient-provider relationship. Suggested remedies include a: patient-centered approach to care, improvement of disease awareness, focus on taking adequate time to provide disease and treatment information as well as treatment adherence, and sensitivity to patient concerns.

    Target Audience:

    Rheumatologists and primary care physicians and other specialists who care for patients with SLE (e.g., dermatologists, nephrologists, OBGYNs); physician assistants, nurse practitioners, and pharmacists who practice in rheumatology; and any other HCPs with an interest in or who clinically encounter patients with SLE.

    By the end of the session the participant will be able to:

    • Describe the pathophysiology of systemic lupus erythematosus (SLE), with a focus on the factors affecting disease progression, remission, and therapeutic mechanisms
    • Recall identification of SLE disease activity, flares, and treatment goals, both short- and long-term
    • Describe the influence of disease activity and corticosteroid use on organ damage in SLE
    • Evaluate available and emerging therapeutic options for SLE, individualizing treatment regimens based on patient and disease characteristics
    • Discuss the role and importance of patient-provider communication in charting a course of optimal treatment
    See full details chevron_right
    • Credit hours: .75
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 12/17/2020
    • Expiration of CME credit: 12/17/2022
  • FREE

    Employing biosimilars in the treatment of inflammatory health conditions: How to and should I?

    Biosimilar drugs are products meant to be similar in quality, safety, and efficacy to an already licensed reference biotherapeutic product. Whereas generics are virtually identical replicas of conventional medications, biosimilars are not the same as the original product – a practically unavoidable outcome because of the considerably large molecular structure that biologics mimic. The literature suggests that learning activities focused on the evolving landscape of biosimilars, which are germane to the therapeutic area because of their potential role in cost containment. Both the FDA and medical literature independently affirm the need for clinician education on biosimilars, including:  comparative efficacy; adverse event rates and management (potential concerns have included immunogenicity); regulatory guidance on interchangeability and substitution – including prescribers retaining some degree of ability to intervene in a product’s substitution at the dispensing stage; and cost considerations.

    Target Audience:

    The following healthcare professionals: Rheumatologists, gastroenterologists, and primary care physicians; physician assistants, nurse practitioners, and pharmacists who practice in the aforementioned areas of specialty; and any other healthcare professionals with an interest in or who clinically encounter patients with the inflammatory disease states covered by this activity.

    By the end of the session the participant will be able to:

    • Describe biosimilar drugs, how they differ from generic drugs, the FDA process for their approval.
    • Describe practical considerations the clinician needs when determining whether to consider when deciding whether substituting or allowing the substitution of a biosimilar medication for its reference medication, and apply them to patient case(s).
    • Describe how biosimilars for inflammatory health conditions are impacting the treatment landscape with respect to number of treatment options, affordability, and safety considerations.
    • Identify the currently available and emerging pharmacotherapeutic treatments for management of inflammatory health conditions and apply them to patient cases using evidence-based medicine.
    • Describe strategies for helping patients understand the implications of using biosimilars.
    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 06/25/2020
    • Expiration of CME credit: 06/25/2022
  • FREE

    ScientiaCME Immunology-Rheumatology CME

    • Cost: Free
    • Credit hours: 2
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Expiration of CME credit: Two years after release